Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis

Technology appraisal guidance
Reference number: TA127
Published: 22 August 2007
Last updated: 21 May 2024

Appendix A: decision paper considered by the Institute's Guidance Executive

Appendix A: decision paper considered by the Institute's Guidance Executive

Appendix A: decision paper considered by the Institute's Guidance Executive
22 December 2010
(45.26 Kb 13 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 22 December 2010